Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$65.2 million.

  • Ocular Therapeutix's Net Income towards Common Stockholders fell 3313.13% to -$65.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$263.5 million, marking a year-over-year decrease of 5962.16%. This contributed to the annual value of -$263.5 million for FY2025, which is 5962.16% down from last year.
  • Per Ocular Therapeutix's latest filing, its Net Income towards Common Stockholders stood at -$65.2 million for Q4 2025, which was down 3313.13% from -$68.0 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Net Income towards Common Stockholders high stood at -$19.5 million for Q1 2022, and its period low was -$68.0 million during Q3 2025.
  • For the 5-year period, Ocular Therapeutix's Net Income towards Common Stockholders averaged around -$34.4 million, with its median value being -$22.9 million (2022).
  • In the last 5 years, Ocular Therapeutix's Net Income towards Common Stockholders soared by 1094.77% in 2022 and then crashed by 11550.88% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Net Income towards Common Stockholders stood at -$19.7 million in 2021, then fell by 5.38% to -$20.8 million in 2022, then dropped by 9.42% to -$22.7 million in 2023, then crashed by 115.51% to -$49.0 million in 2024, then plummeted by 33.13% to -$65.2 million in 2025.
  • Its last three reported values are -$65.2 million in Q4 2025, -$68.0 million for Q3 2025, and -$67.2 million during Q2 2025.